Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Galera Therapeutics Inc (GRTX)

Galera Therapeutics Inc (GRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Galera Therapeutics Inc P.O. Box 134 MALVERN PA 19355 USA

www.galeratx.com P: 610-725-1500

Description:

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel, proprietary therapeutics to transform radiotherapy in cancer. The company's product candidate is GC4419, a highly selective and potent small molecule dismutase mimetic which is designed to rapidly convert superoxide to hydrogen peroxide. Galera Therapeutics, Inc. is headquartered in Malvern, PA.

Key Statistics

Overview:

Market Capitalization, $K 9,633
Enterprise Value, $K -8,627
Shares Outstanding, K 54,392
Annual Sales, $ 0 K
Annual Net Income, $ -59,080 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -5,590 K
EBIT, $ -49,270 K
EBITDA, $ -49,010 K
60-Month Beta 2.02
% of Insider Shareholders 6.90%
% of Institutional Shareholders 50.77%
Float, K 50,639
% Float 93.10%
Short Volume Ratio 0.28

Growth:

1-Year Return -94.54%
3-Year Return -97.73%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.10 on 03/28/24
Latest Earnings Date 05/09/24 [--]
Earnings Per Share ttm -1.41
EPS Growth vs. Prev Qtr 69.70%
EPS Growth vs. Prev Year 82.76%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

GRTX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -137.47%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -2.41
Interest Coverage -4.18
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar